A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.70.2 2, 10.40.2 2, 13.20.2 2, 13.80.2 2, 19.90.2 2, 20.30.2 2, 20.80.2 2, 24.20.2 2, 25.70.2 2, 26.10.2 2, 29.20.2 2, 30.80.2 2. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient.

A crystallization column and a crystallization method. The crystallization column comprises an upper head (1), a tower body (2) and a lower head (3), wherein a crystallization section (11) is provided with a tray (14); and the tray (14) comprises a tray plate (15) and a plurality of lower crystallization members (17). The top end of the lower crystallization member (17) can form a movable connection with the tray plate (15), so that the two adjacent lower crystallizing members (17) are capable of oscillating collisions. The tray (14) may also comprise a plurality of upper crystallization members (21) extending upwardly from the upper surface of the tray plate (15).

A method of purifying an organic material using an ionic liquid according to the present invention includes a sublimation step (S510) of sublimating the organic material containing an impurity, a capturing step (S520) of bringing a sublimated gas of the organic material into contact with the flowing ionic liquid to capture the sublimated gas, and a recrystallization step (S530) of preferentially oversaturating the organic material, which is to be purified, of the sublimated gas, which is captured in the ionic liquid to be dissolved, to thus generate the recrystallized organic material. In the present invention, it is not necessary to perform a process of carrying the sublimated gas, which is generated during the sublimation step, to implement reverse sublimation. Accordingly, there is a merit in that the contamination of a purified sample by an inert carrier gas, which is used in a conventional sublimation purification method, is fundamentally avoided.

The present invention relates to an adduct of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.20.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7,15.2, 15.8, 16.4 23.1, 25.0, 27.80.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Formation of low-crystallinity phytosterol nanoparticles via cooling-controlled supercritical carbon dioxide (SCCO.sub.2) impregnation of phytosterols into biodegradable nanoporous starch aerogels and methods of preparing these aerogels are disclosed. The nanoporous starch aerogels increase water dissolution and bioaccessibility of the phytosterols, thereby making them available for preparation of high nutraceutical value foods.

The present invention relates to a process for purifying a crude diester monomer feedstock comprising: a) a step of mixing the crude diester monomer feedstock with an aqueous solvent, at a temperature of between 60 C. and 150 C., in order to obtain a diester monomer aqueous mixture, the amount of aqueous solvent introduced being adjusted so that the crude diester monomer feedstock represents between 20% and 90% of the total weight of the diester monomer aqueous mixture; b) a step of adsorbing the diester monomer aqueous mixture, at a temperature of between 60 C. and 150 C. and a pressure of between 0.1 and 1.0 MPa, in order to obtain a purified monomer effluent.

The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm.sup.?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30? C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm.sup.?1.

The present invention relates to crystalline 1,2-Propanediol solvate of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide compound of formula-1b, its process for the preparation and its use in the preparation of anhydrous crystalline form (N-6) and monohydrate of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxy ethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide. [formula] 1,2-Propanediol solvate Formula-1b

##STR00001##

Provided are a method for purifying mitomycin C, comprising a step of recrystallizing crude mitomycin C crystals using a high-purity methanol; mitomycin C obtainable by the method; and